Iain McGill
has served on our board of directors since August 2016.
Mr. McGill currently serves as Senior Vice President of Jazz Pharmaceuticals Europe and Rest of World for Jazz Pharmaceuticals Public Limited Company, an international biopharmaceutical company, since March 2015. From March 2014 to
March 2015, Mr. McGill served as Head of EUSA Pharma and Senior Vice President, Jazz Pharmaceuticals, and as Chief Commercial Officer, EUSA Pharma, a specialty pharmaceutical company, from June 2012 to March 2014, when he joined Jazz
Pharmaceuticals in connection with its acquisition of EUSA Pharma. From October 2011 to June 2012, Mr. McGill served as Chief Commercial Officer at EUSA Pharma (Europe) Ltd. From August 2010 to September 2011, he served as President
Europe, International & Global Marketing of EUSA Pharma (Europe) Ltd, and from January 2010 to July 2010, as President of Europe. From 2006 to 2009, Mr. McGill served as Vice President and Global Business Manager at Wyeth, a
pharmaceutical company acquired by Pfizer Inc. Mr. McGill holds a Bachelor of Science degree in Biochemistry from the University of London.
We believe Mr. McGill is qualified to serve on our board of directors because of his leadership experience in the biotechnology and
pharmaceutical industries.
Heather Preston, M.D.
has served on our board of directors since August 2010. Dr. Preston
has served as a managing partner at Pivotal bioVenture Partners, a life sciences venture capital fund, since July 2018. Dr. Preston has also served as a Senior Advisor at TPG Biotech (TPG), a biotechnology venture capital firm, since July 2018,
where she was previously a Partner and Managing Director from May 2005 to July 2018. She has served on the boards of directors of Alder Biopharmaceuticals, Inc., a biopharmaceutical company, since August 2010, of Oxford BioMedica plc, a
biopharmaceutical company, since March 2018 and of Entasis Therapeutics Holdings, Inc., an antibacterial therapies company, since August 2017, and also serves on the boards of a number of private companies. Dr. Preston served on the board of
directors of Albireo Pharma, Inc., a pharmaceutical company, from 2008 to June 2018. Prior to joining TPG, Dr. Preston served for two years as a medical device and biotechnology venture capital investor at JP Morgan Partners, LLC, a private
equity firm. Prior to that, she was an
Entrepreneur-in-Residence
at New Enterprise Associates, a venture capital firm. From 1997 to 2002, Dr. Preston served as a
leader of the pharmaceutical and medical products consulting practice of McKinsey & Co in New York. Dr. Preston holds a B.Sc.Hons degree in biochemistry from the University of London and an M.B.B.Chir degree in medicine from the
University of Oxford. After leaving Oxford, Dr. Preston completed a post-doctoral fellowship in molecular biology at the Dana Farber Cancer Institute, Harvard University. Dr. Preston completed her training in Internal Medicine at the
Massachusetts General Hospital and then
sub-specialized
in Gastroenterology and Hepatology at U.C.S.F. During Dr. Prestons academic career, she was the recipient of a Fulbright Scholarship, a
Fulbright Cancer Research Scholarship, a Harlech Scholarship and a Science and Engineering Research Council Post-doctoral Fellowship Award.
We believe Dr. Preston is qualified to serve on our board of directors because of her experience as an investor in biopharmaceutical and
life sciences companies, her educational background, and leadership in the medical and life science industries.
James B.
Breitmeyer, M.D., Ph.D
.
has served on our board of directors since June 2018. Since September 2015, Dr. Breitmeyer has served as President, Chief Executive Officer and director of Oncternal Therapeutics, Inc. a clinical-stage
oncology biotechnology company. He has been a director of Zogenix, Inc., a pharmaceutical company, since March 2014, and was their acting Chief Medical Officer from August 2012 to February 2013. Previously, Dr. Breitmeyer served as President of
Bavarian Nordic, Inc. and Executive Vice President of Bavarian A/S, a multinational corporation headquartered in Denmark, from February 2013 to July 2015. He previously served as the Executive Vice President of Development and Chief Medical Officer
of Cadence Pharmaceuticals Inc., a pharmaceutical company, from August 2006 to August 2012, and the Chief Medical Officer of Applied Molecular Evolution Inc., a wholly-owned subsidiary of Eli Lilly and Co., a global pharmaceutical company, from
December 2001 to August 2006. Dr. Breitmeyer has also served as President and Chief Executive Officer of the Harvard Clinical Research Institute, and as Chief Medical Officer and Head of Research & Development for North America at
Serono Laboratories Inc., an international biopharmaceutical company. Dr. Breitmeyer served as a founding collaborator and scientific advisor to Immunogen Inc., a
-10-